Jaguar Health (JAGX) announced that its Italian subsidiary, Napo Therapeutics, has submitted a request to the European Medicines Agency to have the EMA’s Committee for Veterinary Medicinal Products provide scientific advice regarding the company’s plan to pursue approval of Canalevia in the European Union for treatment of general diarrhea in dogs based on data from a study Jaguar completed in 200 dogs in 2017. The request asks that the CVMP review the company’s plan and related data during the CVMP’s scheduled meeting in March 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Health secures patent for crofelemer in short bowel syndrome
- Jaguar Health submits amended protocol to FDA for placebo-controlled trial
- Jaguar Health Amends Royalty Interests and Note Terms
- Jaguar Health Reports Q3 2025 Financial Results
- Jaguar Health reports Q3 EPS ($6.28) vs. ($26.29) last year